-->

Company Registry

Asuragen Inc (AKA:Ambion Diagnostics Inc)
Profile last edited on: 2/16/2022

MRNA- and miRNA-based molecular diagnostics for cancer and genetic diseases
Year Founded
2005
First SBIR Year
2006
Latest SBIR Award
2019
Program Status
Active (Acquired)

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2150 Woodward Street Suite 100
Austin, TX 78744
   (877) 777-1874
   corporatebd@asuragen.com
   www.asuragen.com
Multiple Locations:   
Congressional District:   35
County:   Travis

Public Profile

Formerly a subsidiary of Ambion, Inc, in March 2021 it was reported that Asuragen had been acquired by Minneapolis based, Bio-Techne (NASDAQ:TECH). Asuragen functions as a fully integrated diagnostic development company and pharmaceutical services provider with special capabilities in the area of mRNA and miRNA. SBIR-involved since the very early days after founding, the Company¬ís diagnostic product portfolio consists of the first-ever validated microRNA diagnostic assay for pancreatic cancer, quantitative RNA tests for leukemia gene translocations, innovative genetic testing solutions for the fragile X mental retardation (FMR1) gene, Signature¬ģ Oncology products for the qualitative detection of gene translocations and mutations in a variety of hematological and solid tumors, RNA stabilization technologies, and industry-leading controls and standards engineered using its patented Armored RNA technology. Asuragen is empowered with a high level of scientific expertise and assay development capabilities, CLIA and GLP testing services, and an established cGMP manufacturing facility, which allow it to span the spectrum of discovery, testing, production and commercialization for companion diagnostics.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
25-49

Awards Distribution by Agency

Key People / Management

  Matthew McManus -- President and CEO

  Bernard F Andruss -- SVP, Operations and Regulatory Affairs

  Carol E Berry -- Sr. Vp, General Manager Of Genomic Services

  Eran Bram --

  John Brown --

  Justin Brown --

  Rollie Carlson -- Former President and CEO

  Liangjing C Chen --

  Ashish Choudhary --

  Frederick A Fletcher -- Senior VP, Operations

  Bradley Hall --

  Brian Clifton Haynes --

  Colin M Hill -- Senior VP, Commerical Operations

  Lynne Hohlfeld -- CFO; Senior Vice President, Corporate Development

  Jessica Lynn Larson --

  Gary J Latham -- VP, Research and Technology Development

  Elizabeth Mambo --

  Fayyaz Memon -- VP, Regulatory of Clinical Affairs & Quality Assurance

  Doug Sites -- VP, Clia Sales And Marketing

  Jennifer Skeen --

  Sarah Nicole Statt --

  Debra Thompson -- Head of Human Resources

  Matt Winkler -- Chairman of the Board and Cso

  Huiping Zhu --